Ileostomy
Who are we?
It takes about 12 years of research and development before a new medication is put on the market. Each medication must undergo an extensive testing process to ensure that it is both safe and effective. Humans are only involved in the very last steps of this long process, through clinical testing.
At Altasciences, we mainly conduct trials for generic formulations (copies) of medications which are already on the market, but we also conduct trials for new medications.
Participants are crucial to medical research. Without them, no new medication could be approved or improved.
Information About The Current Study
Who are we Seeking? We are recruiting participants between the ages of 18 and 55 who use opioid painkillers recreationally.
How are participants compensated for this study?For completing the clinical trial, you will be compensated up to $5,000.
How long is the study?
The study consists of 1 overnight clinic visits starting in November.
All of the details will be explained by one of our agents over the phone.
What are the advantages of taking part in this study?
By taking part in this study, you will be helping the development of a medication type which could eventually be part of the solution to the opioid epidemic.
In addition, you will be compensated for your time.
More information
How long is the study?
The study consists of 3 clinic visits: two 1-night stays and one visit of just a few hours.
The study dates will be selected based on your availability.
All of the details will be explained by phone.
What are the advantages of taking part in this study?
By taking part in this study, you will be helping the development of a potential new treatment to fight secondary infections caused by taking antibiotics. These infections are a serious health problem, specifically in hospital environments.
In addition, you will be compensated for your time.
What will you bring to this study?
• The drug being developed aims to prevent secondary bacterial infections, including C. difficile, during antibiotic treatment.
• The hypothesis is that new medication will break down the antibiotic in the small intestine and reduce the risk of secondary infections caused by the depletion of bacterial flora in the intestines.
• Patients with an ileostomy enable us to evaluate the effect of the medication by measuring the concentration of the antibiotic directly in the intestines by taking samples of chyme.